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Approximately 5% of patients with
cutaneous melanoma acquire at leastone additional independent melanoma,
a phenomenon known as multiple
primary melanoma (MPM). Geneticfactors are implicated because a family
history is one of the strongest risk fac-
tors for MPM (Ferrone et al., 2005).
One study identified germline muta-
tions in CDKN2A in approximately
15% of MPM patients (Monzon et al.,
1998), and another reported these mu-
tations to be four times more prevalent
in MPM than in patients with single
Figure 1. Delayed cellular senescence in melanocytes from MPM patients. (a) Cumulative growth
curves of melanocytes from MPM (black points, n ¼ 10) and control SPM patients (red points, n ¼ 8). The
first subculture when cells were first counted was designated day 0. At each subsequent subculture, the
fold increase in number of cells was converted to cumulative population doublings. Each point represents
one subculture. See Supplementary Materials and Methods online. (b) Confirmation of cellular
senescence with b-galactosidase immunocytochemistry. Bright-field optics. Left and right images show
representative growing and senescent (high-passage) cells, respectively, from one MPM patient.
Senescent cells display positive b-galactosidase activity (blue) and melanin (grey to black). Scale bar for
both images ¼ 100 mm. MPM, multiple primary melanoma; SPM, single primary melanoma.
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et al., 2008). CDKN2A, the most com-
mon known familial melanoma gene,
encodes p16, a broad-spectrum tumor
suppressor and mediator of cell senes-
cence (Aoude et al., 2015b; Bennett,
2016). Senescence is a permanent
cellular arrest after extensive prolifera-
tion and telomere shortening/dysfunc-
tion, or other genotoxic stresses. p16
induces senescence by inhibiting
CDK4-mediated phosphorylation of
retinoblastoma-family proteins, result-
ing in retinoblastoma proteins binding
and repressing E2F transcription factor
activity, which is needed for S-phase
entry in the cell cycle (Bennett, 2016).
Human cells may senesce through
either the p53 pathway, the p16
pathway, or both. p53 arrests cells by
up-regulating another CDK inhibitor,
p21 (CDKN1A). However, human me-
lanocytes seem to senesce predomi-
nantly through p16. Oncogene (usually
BRAF) activation in an epidermal me-
lanocyte leads to an initial proliferation
followed by senescence, generating a
mole or nevus (Bennett, 2016).
Cell lifespan in vitro is the number
of population doublings completed
by a cell strain before replicative senes-
cence. p16-null melanocytes display an
increased lifespan but still senesce,
through a mechanism involving p21
(Sviderskaya et al., 2003). Similarly,
CDKN2A mutation carriers tend to have
more large nevi than normal (represent-
ing more divisions before senescence)
(Bennett, 2016), as do individuals with
longer telomeres (Bataille et al., 2007).
Moreover, mutations in other
senescence-related genes have been
identified in familial melanoma: TERT,
CDK4, and genes encoding components
of the telomeric cap shelterin, for
example POT1, and TERF2IP (Aoude
et al., 2015a; Robles-Espinoza et al.,
2014; Shi et al., 2014). These observa-
tions suggested thatMPMmaycommonly
be associated with genetically defective
or delayed melanocyte senescence.
This hypothesis has been tested by
explanting melanocyte cultures from
biopsy samples of sun-protected
normal skin from MPM or SPM pa-
tients who are wild type for known
melanoma-associated mutations other
than in MC1R (see Supplementary
Table S1 online). Biopsy samples were
taken with written informed consentand institutional ethical approval. The
use of SPM patients as control subjects
excluded any confounding effect of
simply developing melanoma. Mela-
nocytes were serially passaged until
they reached replicative arrest. Cumu-
lative growth curves for all cultures are
shown (Figure 1a, and see individual
donor information in Supplementary
Figure S1 and Supplementary Table S2
online). Melanocyte culture lifespans
for each patient are included in
Supplementary Table S1. Senescence
was confirmed by b-galactosidase
immunocytochemistry in all lines
(Figure 1b). The final number of popu-
lation doublings (lifespan) per culture
was compared between the groups.
The mean lifespan for MPM patients’
melanocytes (16.3 doublings, n ¼ 10)
was over 4-fold higher than the mean
lifespan for SPM patients’ melanocytes
(3.7 doublings, n ¼ 8), confirming our
hypothesis (P ¼ 0.0057). Normal adult
melanocytes, grown in similar condi-
tions, are reported to have lifespans
ranging up to a maximum of 10population doublings (Graeven and
Herlyn, 1992). The maximum lifespan
we observed among melanocyte cul-
tures from SPM patients was nine dou-
blings, suggesting little difference from
healthy adult donors.
Substantial heterogeneity was
observed among lifespans, especially in
the MPM group. We examined the role
of donor age, because telomere length
shortens with age in some cell types.
Conclusions have varied on the rela-
tionship between donor age and life-
spans of skin fibroblasts (Cristofolo
et al., 1998; Schneider and Mitsui,
1976); this has not been studied in
melanocytes to our knowledge. MPM
cultures showed a significant negative
correlation of lifespan with donor age
(P ¼ 0.0003), whereas SPM cultures
showed no correlation (P ¼ 0.59)
(Figure 2). Slopes of the two regression
lines differed, highly significantly
(P ¼ 0.0046), concluding that the sig-
nificant increase in melanocyte lifespan
from MPM patients occurs indepen-
dently of donor age.www.jidonline.org 767
Figure 2. Relationship of culture lifespan to
donor age. Scatterplot illustrating the relationship
of culture lifespan with donor age from MPM
(black points) and control SPM patients (red
points). Color of regression line matches color of
data points.
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768Although there was no significant
difference in the mean donor age be-
tween MPM and SPM patients
(P ¼ 0.66), there were two MPM pa-
tients younger, and one older, than all
SPM patients. To ensure that the dif-
ference in correlation was not due to
this greater range, these three patients
were excluded from a separate anal-
ysis (see Supplementary Figure S2 on-
line). Slopes were still significantly
different (P ¼ 0.028), and a significant
negative correlation of lifespan with
donor age was still seen only in me-
lanocytes from MPM patients (P ¼
0.027). The mean melanocyte lifespan
from MPM patients was still signifi-
cantly higher than from SPM patients
(P ¼ 0.0064).
The lack of decrease of SPM mela-
nocyte lifespan with donor age agrees
with reports that adult epidermal me-
lanocytes rarely divide, implying little
telomere shortening. Regarding the
MPM cultures, the skin biopsy samples
from MPM patients were, by definition,
taken after diagnosis of a second (or
more) melanoma. Thus, in this group,
young donors were patients who were
young when their second melanoma
arose, and these individuals tended to
have melanocytes with longer lifespans.
This again suggests genetic factors that
increase both MPM susceptibility and
melanocyte lifespan.
These data clearly support a frequent
association of MPM with a genetic
tendency for extended melanocyte
lifespan. Telomere length is associated
with melanoma risk (Burke et al., 2013)Journal of Investigative Dermatology (2017), Volumand nevus size (Bataille et al., 2007).
Likewise, the specific melanoma-
associated mutations in shelterin genes
are predicted to increase telomere
length (Aoude et al., 2015a; Robles-
Espinoza et al., 2014; Shi et al.,
2014). Individuals with longer telo-
meres would be expected to have me-
lanocytes with greater replicative
potential, resulting in greater culture
lifespans, and larger nevi after an
oncogenic mutation, as seen with
CDKN2A defects. This would yield
more cells per nevus, increasing the
risk of further mutations and progres-
sion to melanoma. MPM patients
would make good candidates
for elucidating additional germline
melanoma-susceptibility genes.
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